The Column Group

Funding rounds backed by The Column Group.

Export CSV
Funding disclosed in full
$94M
Median round
$94M
Rounds in calculation
1
1 round
LatestLargest
Funding rounds with company descriptions, amounts, stages and announcement dates
CompanyRoundMarketInvestorsAnnouncedDetails
TriGemX Bio

A clinical-stage biotechnology company developing elismetrep, an investigational oral medicine that blocks TRPM8 channels for the acute treatment of migraine.

$94MUndisclosedBiotechnologyUnited StatesTCGXLeadThe Column GroupLeadViking Global InvestorsLead